Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 169

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 169
---
 billing software during the first decade of the internet.

In all of the aforementioned companies, except
as noted Mr. Bartal has no formal managerial position but is actively involved in these companies’ capital raising efforts and,
technology advancement activities including without limitation, obtaining appropriate intellectual property protection.

Mr. Bartal studied for his BSc in Biology between
1986 and 1989 at Tel Aviv University and the University of Barcelona.

Matti Munk, 53 was appointed a director
on February 18, 2021. Mr. Munk has 20 years of experience in international investment and banking; engaging in international activities,
economics, financing, management. Since 2020, he has served as director and Chief Economist at Comforte Capital. Amazon Aggregator; since
2016, he serves as CEO of Western Wall Street, leading corporate finance and Capital Raises for Israeli Corporations and UK real estate
projects and performing oversight/financial reporting on behalf of investors in local the corporations. Between 2008 and 2016, Mr. Munk
served as manager in International Private Banking. Mercantile Discount Bank. Mr. Munk was responsible for overseeing department and
commercial loans division and establishing and maintaining internal and external relationships with Institutional Market and Family offices.
Mr. Munk received MBA in Finance in 2011 from University of Liverpool, UK and BA in Economics and Finance in 1997 from Bar-Ilan University.

Yoram Drucker,59, was appointed
a director as of February 26, 2025. Mr. Drucker is a serial entrepreneur, founding several companies over the last twenty years and focusing
on the Israeli biotech industry. From October 2017 to November 2023, Mr. Drucker founded and served as Vice President of Business Development
for InnoCan Pharma Ltd., a company traded on the Canadian Stock Exchange. From September 2016 to April 2020, Mr. Drucker was the CEO
and Co-founder of a biotech company, ViruCure, developing an oncolytic-virus based technology platform. Prior to this, he served as the
CEO and Executive Chairman of Cell Source Ltd. from 2011 to 2014. Additionally, Mr. Drucker was a founding member of Brainstorm (NASDAQ:
BCLI), a company publicly traded on the Nasdaq where he served as COO in 2004 and CEO from 2005 to 2007 and a founding member of Pluristem
(NASDAQ